(Reuters) - The results represent a blow to Genzyme, one of the world's biggest biotechnology companies, as tolevamer had been considered one of the more promising drugs in its pipeline.
"These are disappointing results that alter our expectations about the potential for commercializing tolevamer in the near future," said Henri Termeer, Genzyme's chief executive, in a statement.
Read more at Reuters.com Business News
"These are disappointing results that alter our expectations about the potential for commercializing tolevamer in the near future," said Henri Termeer, Genzyme's chief executive, in a statement.
Read more at Reuters.com Business News
No comments:
Post a Comment